EdgeMarket › What Bellevue Group Ag reported owning
What Bellevue Group Ag reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
4.2BPositions
155Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| VRTX VERTEX PHARMACEUTICALS INC / MA | 304.5M | 7.2% | 681.9K | 548.05 | +39.0% |
| ARGX ARGENX SE | 228.6M | 5.4% | 313.0K | 1,039.78 | +57.3% |
| REGN REGENERON PHARMACEUTICALS, INC. | 215.3M | 5.1% | 278.7K | 834.04 | +41.1% |
| SRRK Scholar Rock Holding Corp | 176.2M | 4.2% | 3.6M | 56.50 | +64.2% |
| GILD GILEAD SCIENCES, INC. | 163.0M | 3.9% | 1.2M | 146.12 | +23.1% |
| RVMD Revolution Medicines, Inc. | 150.2M | 3.6% | 1.5M | 209.46 | +479.3% |
| IONS IONIS PHARMACEUTICALS INC | 136.6M | 3.2% | 1.8M | 59.74 | +39.5% |
| ISRG INTUITIVE SURGICAL INC | 132.1M | 3.1% | 286.7K | 378.81 | -21.2% |
| VRDN Viridian Therapeutics, Inc.\DE | 131.6M | 3.1% | 6.7M | 24.29 | +33.9% |
| KRYS Krystal Biotech, Inc. | 124.5M | 3.0% | 481.8K | 346.58 | +137.6% |
| CRNX Crinetics Pharmaceuticals, Inc. | 119.1M | 2.8% | 3.3M | 84.69 | +191.1% |
| ABT ABBOTT LABORATORIES | 118.2M | 2.8% | 1.2M | 116.64 | -11.9% |
| unmapped CUSIP 670703107 | 107.9M | 2.6% | 1.1M | — | — |
| AMGN AMGEN INC | 103.9M | 2.5% | 295.4K | 439.33 | +48.2% |
| BSX BOSTON SCIENTIFIC CORP | 92.0M | 2.2% | 1.5M | 50.37 | -52.5% |
| ELVN Enliven Therapeutics, Inc. | 91.0M | 2.2% | 2.3M | 59.82 | +204.3% |
| IMCR Immunocore Holdings plc | 84.3M | 2.0% | 2.8M | 36.88 | +13.5% |
| MDT Medtronic plc | 83.0M | 2.0% | 957.3K | 93.35 | +0.1% |
| ALNY ALNYLAM PHARMACEUTICALS, INC. | 77.6M | 1.8% | 234.5K | 236.22 | -48.5% |
| RLAY Relay Therapeutics, Inc. | 77.6M | 1.8% | 7.8M | 19.44 | +471.8% |
| SYK STRYKER CORP | 71.4M | 1.7% | 217.2K | 329.45 | -15.9% |
| PCVX Vaxcyte, Inc. | 69.2M | 1.6% | 1.2M | 62.62 | +100.3% |
| VERA Vera Therapeutics, Inc. | 68.8M | 1.6% | 1.7M | 32.27 | +46.0% |
| EW Edwards Lifesciences Corp | 67.2M | 1.6% | 839.5K | 89.79 | +10.3% |
| DMRA Damora Therapeutics, Inc. | 59.5M | 1.4% | 2.3M | 30.82 | +811.9% |
| TNGX Tango Therapeutics, Inc. | 50.2M | 1.2% | 2.4M | 23.88 | +253.8% |
| IDXX IDEXX LABORATORIES INC /DE | 50.1M | 1.2% | 89.1K | 556.93 | -13.0% |
| RARE Ultragenyx Pharmaceutical Inc. | 49.9M | 1.2% | 2.4M | 25.83 | -12.0% |
| DXCM DEXCOM INC | 49.5M | 1.2% | 788.8K | 92.34 | +13.1% |
| JBIO Jade Biosciences, Inc. | 49.2M | 1.2% | 3.5M | 21.34 | +211.5% |
| EWTX Edgewise Therapeutics, Inc. | 48.1M | 1.1% | 1.5M | 44.18 | +219.2% |
| UNH UNITEDHEALTH GROUP INC | 40.1M | 1.0% | 148.2K | 390.11 | +30.1% |
| DHR DANAHER CORP /DE/ | 38.3M | 0.9% | 202.2K | 218.85 | +3.5% |
| CLDX Celldex Therapeutics, Inc. | 38.1M | 0.9% | 1.2M | 40.38 | +93.3% |
| RMD RESMED INC | 35.8M | 0.9% | 159.3K | 231.52 | -19.9% |
| PODD INSULET CORP | 34.3M | 0.8% | 163.7K | 148.16 | -55.5% |
| TMO THERMO FISHER SCIENTIFIC INC. | 31.7M | 0.8% | 64.4K | 629.27 | +27.2% |
| LLY ELI LILLY & Co | 31.2M | 0.7% | 33.9K | 1,255.40 | +78.0% |
| GEHC GE HealthCare Technologies Inc. | 29.7M | 0.7% | 416.9K | 74.82 | +1.3% |
| IRON Disc Medicine, Inc. | 29.4M | 0.7% | 459.3K | 79.81 | +35.9% |
| JNJ JOHNSON & JOHNSON | 29.1M | 0.7% | 119.1K | 270.24 | +51.1% |
| ANNX Annexon, Inc. | 28.6M | 0.7% | 5.2M | 5.07 | +136.9% |
| CI Cigna Group | 26.2M | 0.6% | 98.3K | 277.51 | -8.9% |
| ORKA Oruka Therapeutics, Inc. | 24.9M | 0.6% | 507.0K | 107.96 | +649.7% |
| MRK Merck & Co., Inc. | 24.9M | 0.6% | 206.6K | 152.55 | +80.2% |
| ALGN ALIGN TECHNOLOGY INC | 23.9M | 0.6% | 139.7K | 162.55 | +13.2% |
| STE STERIS plc | 22.1M | 0.5% | 99.9K | 237.93 | -4.7% |
| GMED GLOBUS MEDICAL INC | 21.3M | 0.5% | 247.3K | 86.91 | +43.1% |
| GLUE Monte Rosa Therapeutics, Inc. | 20.6M | 0.5% | 1.2M | 14.30 | +222.8% |
| ABBV AbbVie Inc. | 20.3M | 0.5% | 93.6K | 264.96 | +26.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →